JPS6344843A - O/w/o-type emulsified oil and fat composition - Google Patents
O/w/o-type emulsified oil and fat compositionInfo
- Publication number
- JPS6344843A JPS6344843A JP61189755A JP18975586A JPS6344843A JP S6344843 A JPS6344843 A JP S6344843A JP 61189755 A JP61189755 A JP 61189755A JP 18975586 A JP18975586 A JP 18975586A JP S6344843 A JPS6344843 A JP S6344843A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- unsaturated fatty
- fat composition
- acid
- highly unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 24
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 24
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- -1 diglyceride Chemical compound 0.000 claims abstract description 8
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 abstract description 24
- 235000013305 food Nutrition 0.000 abstract description 5
- 239000011732 tocopherol Substances 0.000 abstract description 5
- 229930003799 tocopherol Natural products 0.000 abstract description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 abstract description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 3
- 239000005642 Oleic acid Substances 0.000 abstract description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 3
- 235000021313 oleic acid Nutrition 0.000 abstract description 3
- 235000010384 tocopherol Nutrition 0.000 abstract description 3
- 229960001295 tocopherol Drugs 0.000 abstract description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 3
- 235000021342 arachidonic acid Nutrition 0.000 abstract description 2
- 229940114079 arachidonic acid Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 44
- 235000019198 oils Nutrition 0.000 description 44
- 239000003925 fat Substances 0.000 description 22
- 239000012071 phase Substances 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は高度不飽和脂肪酸を安定に配合した油中水中油
型乳化油脂組成物に関し、更に詳細には内相油に高度不
飽和脂肪酸を含有せしめた。成人病を予防することので
きる油中水中油型乳化油脂組成物に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an oil-in-water type emulsified fat composition stably containing highly unsaturated fatty acids, and more specifically, the present invention relates to an oil-in-water type emulsified oil composition that stably contains highly unsaturated fatty acids, and more specifically, Contained. The present invention relates to an oil-in-water emulsified oil composition that can prevent adult diseases.
リノール酸、γ−リルン酸、オレイン酸、エイコサペン
タエン酸、ドコサヘキサエン酸等の高度不飽和脂肪酸は
、血中コレステロール濃度の正常化、血小板凝集抑制作
用、心筋収縮力の増大作用冠流量の増加作用、血圧低下
作用、糖尿柄性網膜症の予防・治療作用を有する他、細
胞を構成する生体膜の構造材料として非常に重要な働き
をしていることが知られている。Polyunsaturated fatty acids such as linoleic acid, γ-lylunic acid, oleic acid, eicosapentaenoic acid, and docosahexaenoic acid have the effect of normalizing blood cholesterol concentration, suppressing platelet aggregation, increasing myocardial contractility, increasing coronary flow, In addition to having blood pressure lowering effects and preventive and therapeutic effects on diabetic retinopathy, it is known to play a very important role as a structural material for biological membranes that make up cells.
しかしながら、この高度不飽和脂肪酸は非常に酸化され
易く、生じた過酸化物が匂い、味を悪くすると共に、生
体内に取り入Cられた場合、過酸化脂質が生体膜を破壊
したり、組織に沈着し、生体機能の衰退を起し、疾患の
原因となる。However, this highly unsaturated fatty acid is very easily oxidized, and the peroxide produced causes a bad odor and taste, and when taken into the body, the lipid peroxide can destroy biological membranes and damage tissues. It is deposited, causing a decline in biological functions and causing disease.
従来、0のような過酸化物の生成を抑制する目的で、高
度不飽和脂肪酸をソフトゼラチンカプセル中で、あるい
は窒素雰囲気トで保存したり、また、トコフェロール等
の抗酸化剤と共存せしめているが不充分で゛あった。Conventionally, in order to suppress the production of peroxides such as 0, polyunsaturated fatty acids have been stored in soft gelatin capsules or in a nitrogen atmosphere, or coexisted with antioxidants such as tocopherols. was insufficient.
また、これ、らの高度不飽和脂肪酸は、液状油その−1
まの形゛÷摂取すると椎体利用率が低いということ本知
られていた。In addition, these highly unsaturated fatty acids are liquid oil No. 1
It is well known that if the body is ingested, the vertebral body utilization rate will be low.
したがって、高度不飽和脂肪酸の生理作用を充分発揮さ
せ、成人病予防効果を期待する為に、高度不飽和脂肪酸
を安定に配合し、しかも吸収性の良い組成物の開発が要
望されていた。−〔問題を解決するための手段〕
本発明者らは、上記問題点を解決すべく、種々研究をお
こなった結果、高度不飽和脂肪酸を、内相油を水相中に
乳化させた水中油型エマルジョン □(以下[0,/W
エマルジョン」といり)を、更に外相油O7中に乳化分
散させて得た油中水中油型(以下r o+/ W/ 0
2型]という)エマルジョン中に配合すれば、長鎖高度
不飽和脂肪酸の吸収が良くなると共に、同脂肪酸が安定
化されることを見い出し、本発明を完成した。Therefore, in order to fully demonstrate the physiological effects of highly unsaturated fatty acids and to expect the effect of preventing adult diseases, there has been a demand for the development of a composition that stably contains highly unsaturated fatty acids and has good absorbability. - [Means for Solving the Problems] In order to solve the above problems, the present inventors have conducted various studies and found that highly unsaturated fatty acids can be added to a water-in-water oil prepared by emulsifying internal phase oil in an aqueous phase. Type emulsion □ (hereinafter [0,/W
An oil-in-water type (hereinafter referred to as "ro+/W/0") obtained by further emulsifying and dispersing the "emulsion" in external phase oil O7
The present inventors have discovered that long-chain polyunsaturated fatty acids can be absorbed better and stabilized when incorporated into an emulsion (called type 2), and have completed the present invention.
すなわち、本発明は長鎖高度不飽和脂肪酸ま九はそのエ
ステル誘導体を内相油中に含有したことを特徴とするO
、/W10□型乳化油型組化油脂組成物るものである。That is, the present invention is characterized in that long-chain highly unsaturated fatty acids or their ester derivatives are contained in the internal phase oil.
, /W10□ type emulsified oil type assembled oil and fat composition.
本発明のO2/W10t型乳化油脂組成物(以下「油脂
組成物」という)に使用する長鎖高度不飽和脂肪酸(以
ド「不飽和脂肪酸」という)としては、リノール酸、r
゛−リルン酸、オレイン酸、アラキドン酸、エイコサペ
ンタエン酸、ドコサヘキサエン酸が挙げ、られる。これ
らはそのまま、あるいは、トリグリセリド、ジグリセリ
ド、モノグリセリドまたはエチルエステル等の誘導体と
して用いられる。The long-chain highly unsaturated fatty acids (hereinafter referred to as "unsaturated fatty acids") used in the O2/W10t type emulsified fat composition (hereinafter referred to as "oil composition") of the present invention include linoleic acid, r
Examples include lylunic acid, oleic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. These can be used as they are or as derivatives such as triglycerides, diglycerides, monoglycerides or ethyl esters.
本発明の油脂組成物は、内相油に上記不飽和脂肪酸又は
そのエステル誘導体を含有せしめる以外は公知の方法に
より調製することができる。例えば、内相油(0,)成
分と水相′(W)成分を混合し、予備乳化後、これを3
0“〜80°C1好ましくは50’〜70°Cでホモゲ
ナイザーにかけ0./Wエマルジョンを得る。次いで外
相油(02)成分を40’〜70℃、好ましくは50″
〜60℃に加熱し、これに上記0./Wエマルジョンを
加え混合後、急冷練合せをすることにより製造される。The oil and fat composition of the present invention can be prepared by a known method except that the internal phase oil contains the unsaturated fatty acid or its ester derivative. For example, the internal phase oil (0,) component and the water phase' (W) component are mixed, and after pre-emulsification, this is
0" to 80°C1, preferably at 50' to 70°C, to obtain a 0./W emulsion. Next, add the external phase oil (02) component to 40' to 70°C, preferably 50"
Heat to ~60°C and add the above 0. /W emulsion is added and mixed, and then rapidly cooled and kneaded.
内相油には不飽和脂肪酸及びそのエステルのほかに抗酸
化性のある物質を加え、不飽和脂肪酸の効果と安定性を
さらに向上させることが可能である。抗酸化剤としては
、−膜内に食品の抗酸化剤として用いられているトコフ
ェロール類、ブチぶヒドロキシアニソール、ジブチルヒ
ドロキシトルエン、エリソルビン酸、エリソルビン酸ナ
トリウム等が使用される。またその他に抗酸化能を有す
る香辛料、生薬の抽出物、粉末、精油抽出残渣等が用い
られる。抗酸化能を有する香辛料、生薬としてハマビシ
科、ゆそうぼ((Guajacum officina
−11e ’)に含有するグアヤク脂、ヒマワリ種子、
大豆油等に含まれる天然トコフェロール、五倍子、没食
子に含まれるタンニンの加水分解産物である没食子酸、
胡麻油に含まれるセザモール、綿実油に含すれるゴシポ
ール、ローズマリー、セージ、タイム、オレガノ等があ
る。これらの抗酸化性物質のうチ、%にトコフェロール
、ローズマリー、セ一ジ等の生薬・香辛料由来のものが
よい。It is possible to further improve the effectiveness and stability of unsaturated fatty acids by adding antioxidant substances to the internal phase oil in addition to unsaturated fatty acids and their esters. As the antioxidant, tocopherols, butyhydroxyanisole, dibutylhydroxytoluene, erythorbic acid, sodium erythorbate, etc., which are used as antioxidants in foods, are used in the membrane. In addition, spices, extracts of herbal medicines, powders, essential oil extraction residues, etc., which have antioxidant properties, are used. As a spice with antioxidant ability and as a herbal medicine, it is used as a herbal medicine.
-11e') guaiac oil, sunflower seeds,
Natural tocopherol contained in soybean oil, etc., gallic acid, which is a hydrolysis product of tannin contained in gallic acid,
These include sezamol found in sesame oil, gossypol found in cottonseed oil, rosemary, sage, thyme, and oregano. Among these antioxidant substances, those derived from herbal medicines and spices such as tocopherol, rosemary, and sedge are good.
また、本発明の油脂組成物において用いられる油脂とし
ては、食用油脂が好ましく、その種類については、特に
制限されず、大豆油、ナタネ油、パーム油、コーン油1
、綿実油、ヤシ油、パーム核油等の植物油脂類、乳脂、
牛脂、ラード、魚油、鯨油等の動物油脂類のいずれも使
用することができ、また、これらをエステル交換したも
のも使用することができる。また、この外相油には、必
要に応じて、グリセリン脂肪酸モノエステル、ショ糖脂
肪酸エステル、プロプレンゲリコール脂肪酸エステル、
ソルビタン脂肪酸部分エステル、ポリオキシエチレンソ
ルビタン脂肪酸部分エステル、レシチン等の乳化剤を併
用することができる。In addition, the fats and oils used in the fat and oil composition of the present invention are preferably edible fats and oils, and the types thereof are not particularly limited, including soybean oil, rapeseed oil, palm oil, and corn oil.
, vegetable oils such as cottonseed oil, coconut oil, palm kernel oil, milk fat,
Any of animal fats and oils such as beef tallow, lard, fish oil, and whale oil can be used, and transesterified products of these can also be used. In addition, this external phase oil may contain glycerin fatty acid monoester, sucrose fatty acid ester, proprene gelicol fatty acid ester,
Emulsifiers such as sorbitan fatty acid partial ester, polyoxyethylene sorbitan fatty acid partial ester, and lecithin can be used in combination.
更に本発明の油脂組成物におけろ水相は特に制限されな
いが、該水相には従来よりO/W型エマルジョンに用い
られている、カゼインを主体とする乳タンパク質を加え
るのが好ましい。この乳タンシクク質としては、具体的
には、ミルクカゼイン、カゼインナトリウム、カゼイン
カルシウム、レンネットカゼイン及び脱脂粉乳等があげ
られる。Further, the aqueous phase in the oil and fat composition of the present invention is not particularly limited, but it is preferable to add to the aqueous phase a milk protein mainly composed of casein, which has been conventionally used in O/W emulsions. Specific examples of the milk protein include milk casein, sodium caseinate, calcium caseinate, rennet casein, and skim milk powder.
本発明の油脂組成物中の不飽和脂肪酸の量は特に制限さ
れるものではないが、油脂組成物全量に対して、目的と
する不飽和脂肪酸の1日当たりの摂取槽から決めるべき
である。食品油脂に含有される不飽和脂肪酸量は食品油
脂の起源によシ異なるが、通常O〜10チ程度である。The amount of unsaturated fatty acids in the oil and fat composition of the present invention is not particularly limited, but should be determined based on the desired daily intake of unsaturated fatty acids with respect to the total amount of the oil and fat composition. The amount of unsaturated fatty acids contained in food fats and oils varies depending on the origin of the food fats and oils, but is usually about 0 to 10%.
一方必須脂肪酸の成人男子の最少必要量は全脂質に対し
て1チ程度である。従って本発明エマルジョン中の内相
油に含有させる不飽和脂肪酸含量は1チ以上、好ましく
け2チ以上が良い。捷だ抗酸化剤の添加量は食品添加物
として認められる量、すなわち0.1チである。従って
本発明エマルジョン中に添加する量は0.01〜0.1
チ、好ましくは0.05〜0.1チである。ただしdQ
−α−トコフェロールはこの限りではなく任意量添力口
することができる。On the other hand, the minimum required amount of essential fatty acids for adult males is about 1 ti of total fat. Therefore, the content of unsaturated fatty acids contained in the internal phase oil in the emulsion of the present invention is preferably 1 or more, preferably 2 or more. The amount of added antioxidant is the amount recognized as a food additive, that is, 0.1%. Therefore, the amount added to the emulsion of the present invention is 0.01 to 0.1
H, preferably 0.05 to 0.1 H. However, dQ
-α-Tocopherol is not limited to this, and any amount can be added.
また、本発明の0./W102型乳化油型組化油脂組成
物内相油01、水相W、外相油O7の重量割合は、内相
油(J、10〜40%、水相w’to〜40チ、外相油
0.20〜30チの範囲が好ましい。Moreover, 0.0 of the present invention. /W102 type emulsified oil type assembled oil and fat composition The weight ratios of inner phase oil 01, water phase W, and outer phase oil O7 are as follows: inner phase oil (J, 10-40%, water phase w'to-40%, outer phase oil A range of 0.20 to 30 inches is preferred.
本発明の01/W10!型乳化油脂組成物には、更に必
要に応じ、上記のカゼインを主体とする乳タンパク質等
以外の乳製品、香料、着色料、調味料、甘味料、゛糖類
、食塩、果汁、及びジャム等を添加することができ、ま
た、Q+ / W、 / ox型型化化油脂組成物安定
性を高めるために、ゼラチン等の乳化安定用糊料等の物
質を添加しても良い。01/W10 of the present invention! The type emulsified fat composition may further contain dairy products other than the casein-based milk proteins mentioned above, fragrances, colorants, seasonings, sweeteners, saccharides, salt, fruit juice, jam, etc., as necessary. Furthermore, in order to improve the stability of the Q+/W,/ox type shaped oil and fat composition, substances such as thickeners for emulsion stabilization such as gelatin may be added.
本発明の油脂組成物は、不飽和脂肪酸及びそのエステル
を安定に保ち、しかもその吸収を曳くすることができる
ので高コレステロール血症、動脈硬化症、血栓症、糖尿
病性網膜症等の治療、予防のための医薬、栄養食品等と
して有用なものである。The oil and fat composition of the present invention can keep unsaturated fatty acids and their esters stable and prevent their absorption, so it can treat and prevent hypercholesterolemia, arteriosclerosis, thrombosis, diabetic retinopathy, etc. It is useful as a medicine, nutritional food, etc.
以下に実施例・比較例を挙げ本発明の詳細な説明するが
、本発明はこれらあ実施例に限定されるものではない。The present invention will be described in detail below with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
実施例1
下に示す組成の油脂組成物を調製し、内相油に含まれた
リノール酸の安定性を検討した。この結果を第1表に示
す。なP、比較品としてはW10型エマルジョンの組成
物を用いた。Example 1 An oil and fat composition having the composition shown below was prepared, and the stability of linoleic acid contained in the internal phase oil was examined. The results are shown in Table 1. As a comparison product, a W10 type emulsion composition was used.
(組成)
本発明組成物1=
内相油01 リノール酸 50
pまず上記の内相油O1成分と上記の水相W成分を混合
、予備乳化後、これを70℃でホモジナイザーを通し、
0./Wエマルジョンを得た。次いで別途用意した上記
の外相油O7成分を60℃に加熱し、これに上記の01
/Wエマルジヨンを加え、混合後、急冷練合せをして、
本発明の0./VJ102型乳化油脂粗乳化油脂組成
物9)
本発明組成物2=
本発明組成物1と全て同様にしてO+ / W / O
t型型化化油脂組成物得た。(Composition) Composition of the present invention 1 = Internal phase oil 01 Linoleic acid 50
p First, the above internal phase oil O1 component and the above water phase W component were mixed and pre-emulsified, and then passed through a homogenizer at 70°C.
0. /W emulsion was obtained. Next, the above-mentioned external phase oil O7 component prepared separately was heated to 60°C, and the above-mentioned 01 was added to it.
/W emulsion is added, mixed, and then rapidly cooled and kneaded.
0 of the present invention. /VJ102 type emulsified oil/fat crude emulsified oil/fat composition 9) Invention composition 2 = O+ / W / O in the same manner as in invention composition 1
A T-shaped oil and fat composition was obtained.
比較品1:
油相成分Oと水成分Wを混合、予備乳化後、これを70
℃でホモジナイザーを通し、W10エマルジョンを得た
。Comparative product 1: Oil phase component O and water component W were mixed, pre-emulsified, and mixed at 70%
A W10 emulsion was obtained by passing through a homogenizer at °C.
比較品2; 比較品1と全て同様にしてW10エマルジョンを得た。Comparison product 2; A W10 emulsion was obtained in the same manner as Comparative Product 1.
(試験方法)
各組成物を40℃、相対湿度70チで3カ月間保存し、
保存後の組成物の過酸化物価を測定することにより安定
性を判断した。(Test method) Each composition was stored at 40°C and relative humidity of 70°C for 3 months,
Stability was determined by measuring the peroxide value of the composition after storage.
(結 果)
第 1 表
以上の結果から本発明エマルジョンは明らかにリノール
酸を安定化させることが確認された。(Results) From the results shown in Table 1, it was confirmed that the emulsion of the present invention clearly stabilizes linoleic acid.
実施例2
実施例1で作成した本発明組成物1〜2及び比較品1〜
2のエマルジョンを、ウィスター系雄性ラット(体重2
00P)に3dずつ30日間胃内投与した。投与最終日
に断頭層殺し、採血後、血清中のコレステロール濃度を
測定した。また対照として水投与群を設けた。この結果
を第2表に示す。Example 2 Compositions 1-2 of the present invention prepared in Example 1 and Comparative products 1-
2 emulsion was applied to male Wistar rats (body weight 2
00P) was administered intragastrically for 30 days. On the final day of administration, the rats were decapitated, blood was collected, and the serum cholesterol concentration was measured. A water administration group was also provided as a control. The results are shown in Table 2.
第2表
以上の結果から、本発明エマルジョンはリノール酸をよ
り安定化させ、生理作用を充分に引き出し得ることが明
らかとなった。From the results shown in Table 2 and above, it is clear that the emulsion of the present invention can further stabilize linoleic acid and fully bring out its physiological effects.
以上that's all
Claims (1)
内相油中に含有したことを特徴とする油中水中油型乳化
油脂組成物。 2、長鎖高度不飽和脂肪酸のエステル誘導体が長鎖高度
不飽和脂肪酸のトリグリセリド、ジグリセリド、モノグ
リセリドまたはエチルエステルである特許請求の範囲第
1項記載の油中水中油型乳化油脂組成物。 3、内相油中に更に抗酸化剤を含有した特許請求の範囲
第1項記載の油中水中油型乳化油脂組成物。[Scope of Claims] 1. An oil-in-water emulsified fat composition characterized by containing a long-chain highly unsaturated fatty acid or its ester derivative in the internal phase oil. 2. The oil-in-water emulsified fat composition according to claim 1, wherein the ester derivative of a long-chain highly unsaturated fatty acid is a triglyceride, diglyceride, monoglyceride, or ethyl ester of a long-chain highly unsaturated fatty acid. 3. The oil-in-water emulsified fat composition according to claim 1, which further contains an antioxidant in the internal phase oil.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61189755A JPS6344843A (en) | 1986-08-13 | 1986-08-13 | O/w/o-type emulsified oil and fat composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61189755A JPS6344843A (en) | 1986-08-13 | 1986-08-13 | O/w/o-type emulsified oil and fat composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6344843A true JPS6344843A (en) | 1988-02-25 |
Family
ID=16246635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61189755A Pending JPS6344843A (en) | 1986-08-13 | 1986-08-13 | O/w/o-type emulsified oil and fat composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6344843A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63297323A (en) * | 1987-05-07 | 1988-12-05 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツ プリカーシヨン・シヤンテイフイツク・(エス.セー.エール.アー.エス) | Ophthalmic drug |
WO1991010371A1 (en) * | 1990-01-09 | 1991-07-25 | Kabushiki Kaisha Advance | Acat enzyme inhibiting composition |
WO2005052102A1 (en) * | 2003-11-28 | 2005-06-09 | Onbio Corporation | A composition enriched in diglyceride with conjugated linoleic acid |
JP2005527479A (en) * | 2001-10-11 | 2005-09-15 | ユニベルシタト デ レス イルレス バレアルス | Use of hydroxyoleic acid and similar compounds in the manufacture of pharmaceuticals |
WO2008044550A1 (en) * | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
US7741500B2 (en) | 2004-11-04 | 2010-06-22 | Monsanto Technology Llc | Processes for preparation of oil compositions |
WO2012111225A1 (en) * | 2011-02-18 | 2012-08-23 | 株式会社J-オイルミルズ | Water-in-oil type emulsified oil/fat composition |
US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
US9701947B2 (en) | 2003-08-21 | 2017-07-11 | Monsanto Technology Llc | Fatty acid desaturases from primula |
US9816100B2 (en) | 2009-09-15 | 2017-11-14 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
US9873887B2 (en) | 2006-03-10 | 2018-01-23 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
US11034983B2 (en) | 2004-04-16 | 2021-06-15 | Monsanto Technology Llc | Expression of fatty acid desaturases in corn |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55120745A (en) * | 1979-03-09 | 1980-09-17 | Asahi Denka Kogyo Kk | Oil-in-water-in-oil type double emulsified oil composition |
JPS58143829A (en) * | 1982-02-18 | 1983-08-26 | Kao Corp | Preparation of double emulsified oil or fat composition |
JPS58165732A (en) * | 1982-03-26 | 1983-09-30 | 花王株式会社 | Emulsified oil and fat composition for manufacturing confectionery |
JPS609448A (en) * | 1983-06-28 | 1985-01-18 | Sooma:Kk | Additive for health food |
JPS6091940A (en) * | 1983-10-24 | 1985-05-23 | Yoshihara Seiyu Kk | Solid oil and fat product for cooking |
JPS60192547A (en) * | 1984-03-14 | 1985-10-01 | Nippon Oil & Fats Co Ltd | Edible liquid compounded oil |
-
1986
- 1986-08-13 JP JP61189755A patent/JPS6344843A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55120745A (en) * | 1979-03-09 | 1980-09-17 | Asahi Denka Kogyo Kk | Oil-in-water-in-oil type double emulsified oil composition |
JPS58143829A (en) * | 1982-02-18 | 1983-08-26 | Kao Corp | Preparation of double emulsified oil or fat composition |
JPS58165732A (en) * | 1982-03-26 | 1983-09-30 | 花王株式会社 | Emulsified oil and fat composition for manufacturing confectionery |
JPS609448A (en) * | 1983-06-28 | 1985-01-18 | Sooma:Kk | Additive for health food |
JPS6091940A (en) * | 1983-10-24 | 1985-05-23 | Yoshihara Seiyu Kk | Solid oil and fat product for cooking |
JPS60192547A (en) * | 1984-03-14 | 1985-10-01 | Nippon Oil & Fats Co Ltd | Edible liquid compounded oil |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63297323A (en) * | 1987-05-07 | 1988-12-05 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツ プリカーシヨン・シヤンテイフイツク・(エス.セー.エール.アー.エス) | Ophthalmic drug |
WO1991010371A1 (en) * | 1990-01-09 | 1991-07-25 | Kabushiki Kaisha Advance | Acat enzyme inhibiting composition |
JP2005527479A (en) * | 2001-10-11 | 2005-09-15 | ユニベルシタト デ レス イルレス バレアルス | Use of hydroxyoleic acid and similar compounds in the manufacture of pharmaceuticals |
JP4737931B2 (en) * | 2001-10-11 | 2011-08-03 | ユニベルシタト デ レス イルレス バレアルス | Use of hydroxyoleic acid and similar compounds in the manufacture of pharmaceuticals |
US11041148B2 (en) | 2003-08-21 | 2021-06-22 | Monsanto Technology Llc | Fatty acid desaturases from primula |
US10174297B2 (en) | 2003-08-21 | 2019-01-08 | Monsanto Technology Llc | Fatty acid desaturases from primula |
US9701947B2 (en) | 2003-08-21 | 2017-07-11 | Monsanto Technology Llc | Fatty acid desaturases from primula |
WO2005052102A1 (en) * | 2003-11-28 | 2005-06-09 | Onbio Corporation | A composition enriched in diglyceride with conjugated linoleic acid |
US11034983B2 (en) | 2004-04-16 | 2021-06-15 | Monsanto Technology Llc | Expression of fatty acid desaturases in corn |
US7741500B2 (en) | 2004-11-04 | 2010-06-22 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US9284511B2 (en) | 2004-11-04 | 2016-03-15 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US8247584B2 (en) | 2004-11-04 | 2012-08-21 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US8057835B2 (en) | 2004-11-04 | 2011-11-15 | Monsanto Technology Llc | Seed oil compositions |
US9961916B2 (en) | 2004-11-04 | 2018-05-08 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US7902388B2 (en) * | 2004-11-04 | 2011-03-08 | Heise Jerald D | High PUFA oil compositions |
US8586773B2 (en) | 2004-11-04 | 2013-11-19 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US10314317B2 (en) | 2004-11-04 | 2019-06-11 | Monsanto Technology Llc | Seed oil compositions |
US8901299B2 (en) | 2004-11-04 | 2014-12-02 | Monsanto Technology Llc | Processes for preparation of oil compositions |
US9410108B2 (en) | 2004-11-04 | 2016-08-09 | Monsanto Technology Llc | Seed oil compositions |
US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
US9873887B2 (en) | 2006-03-10 | 2018-01-23 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
US10570406B2 (en) | 2006-03-10 | 2020-02-25 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
JP4829963B2 (en) * | 2006-10-04 | 2011-12-07 | サントリーホールディングス株式会社 | Lignan compounds containing O / W / O type emulsion and composition containing the same |
JPWO2008044550A1 (en) * | 2006-10-04 | 2010-02-12 | サントリーホールディングス株式会社 | Lignan compounds containing O / W / O type emulsion and composition containing the same |
AU2007305614B2 (en) * | 2006-10-04 | 2012-08-23 | Suntory Holdings Limited | O/W/O emulsion containing lignan compounds and composition containing the same |
WO2008044550A1 (en) * | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
US9816100B2 (en) | 2009-09-15 | 2017-11-14 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
US10208315B2 (en) | 2009-09-15 | 2019-02-19 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
JP5036091B1 (en) * | 2011-02-18 | 2012-09-26 | 株式会社J−オイルミルズ | Water-in-oil emulsified fat composition |
WO2012111225A1 (en) * | 2011-02-18 | 2012-08-23 | 株式会社J-オイルミルズ | Water-in-oil type emulsified oil/fat composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1931212B1 (en) | Dietary supplements and prepared foods containing triglyceride-recrystallized non-esterified phytosterols | |
US7045143B1 (en) | Fat blend | |
RU2376782C2 (en) | Oil composition and food products that contain it, pharmaceutical composition and food additive | |
JP4870430B2 (en) | Composition for prevention and treatment of varicose veins | |
JP2002053892A (en) | Oil or fat composition | |
JPH0649479A (en) | Stabilization of omega,3-unsaturated fatty acid compound | |
JPS59172416A (en) | Fat transfusion solution | |
JP3941073B2 (en) | Oil and fat composition and food containing the same | |
JPS6344843A (en) | O/w/o-type emulsified oil and fat composition | |
JPH07305088A (en) | Powdery oil and fat composition | |
JPS60105471A (en) | Production of health food egg | |
JP5118284B2 (en) | Oil-in-water emulsion composition | |
ES2298224T3 (en) | NATURAL VEGETABLE OIL CONCENTRATED IN INSAPONIFICABLE AS FOOD INGREDIENT. | |
JPH0563140B2 (en) | ||
JPH06172782A (en) | Powder of fat and oil containing highly unsaturated fatty acid | |
JPH04152861A (en) | Nutrient composition for nutrition | |
JPH06169735A (en) | Nutritious drink composition | |
JPS6344842A (en) | O/w/o-type emulsified oil and fat composition | |
JPS63297342A (en) | Synthetic oil or fat and fatty emulsion infusion solution and tube feeding agent containing said oil or fat | |
JPH0336493B2 (en) | ||
JP2001211827A (en) | Edible oil composition containing long-chain alcohol and method of producing the same | |
JPH03297364A (en) | Powdery composition for preventing thrombosis | |
Christophersen et al. | Effects of microencapsulation on bioavailability of fish oil omega‐3 fatty acids | |
JP2003135022A (en) | Coenzyme q10 | |
JPS61135572A (en) | Fat emulsion for intestinal use |